IL44877A - Allopurinol tablet formulation - Google Patents
Allopurinol tablet formulationInfo
- Publication number
- IL44877A IL44877A IL44877A IL4487774A IL44877A IL 44877 A IL44877 A IL 44877A IL 44877 A IL44877 A IL 44877A IL 4487774 A IL4487774 A IL 4487774A IL 44877 A IL44877 A IL 44877A
- Authority
- IL
- Israel
- Prior art keywords
- tablet formulation
- allopurinol
- formulation according
- agent
- particle size
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1460302 Allopurinol tablet formulations WELLCOME FOUNDATION Ltd 23 May 1974 [23 May 1973] 24628/73 Heading A5B Tablet formulations comprise from 80 to 98% w/w of allopurinol (4-hydroxy pyrazolo (3, 4-d) pyrimidine) having a particle size from 2 to 40Ám, from 1 to 19% w/w of a disintegrating agent and from 1 to 19% of a granulating agent. The disintegrating agent may be alginic acid, a sodium starch glycolate, a guar-based vegetable gum or calcium carboxymethyl cellulose and the granulating agent may be starch mucilage, a starch derivative, a cellulose derivative, polyvinylpyrrolidine or gelatin. The formulations are compressed on standard machinery to form tablets for use in treating gout and other hyperuricaemic conditions.
[GB1460302A]
Claims (20)
1. A 429 (F) What we claim is:- 1. A tablet formulation, which comprises from 80 to 98% (w/w) of allopurinol having a particle size, as herein before defined, from 2 to 40μπι, from 1 to 19% (w/w) of a disintegrating agent and from 1 to 19% (w/w) of a granulating agent.
2. A tablet formulation according to claim 1, which comprises at least 85% (w/w) of allopurinol.
3. A tablet formulation according to claim 2, which comprises at least 90% (w/w) of allopurinol.
4. A tablet formulation according to claim 3, which comprises about 95% (w/w) of allopurinol.
5. A tablet formulation according to any one of the preceding claims, which comprises less than 5% (w/w) of a granulating agent.
6. A tablet formulation according to claim 5, which comprises about 2% (w/w) of a granulating agent.
7. A tablet formulation according to any one of the preceding claims, which comprises less than 5% (w/w) of a disintegrating agent.
8. A tablet formulation according to claim 7, which comprises about 2% (w/w) of a disintegrating agent.
9. A tablet formulation according to any one of the preceding claims, which comprises from 250 to 350 mg of allopurinol. A 429 (F)
10. A tablet formulation according to claim 9, which comprises about 300 mg of allopurinol.
11. A tablet formulation according to any one of claims 1 to 8, which comprises from 50 to 150 mg of allopurinol.
12. A tablet formulation according to claim 11, which comprises about 100 mg of allopurinol.
13. A tablet formulation according to any one of the preceding claims, which comprises allopurinol having a particle size from 28 to 38μϊη.
14. . A tablet formulation according to any one of claims 1 to 12, which comprises allopurinol having a particle size less than 28μπι.
15. A tablet formulation according to claim 14, which comprises allopurinol having a particle size less than 15μπι.
16. A tablet formulation according to claim 15, which comprises allopurinol having a particle size of about ΙΟμιη.
17. A tablet formulation according to any one of the preceding claims, wherein the disintegrating agent is Primojel.
18. A tablet formulation according to any one of the preceding claims, wherein the granulating agent is gelatin. A 429 (M)
19. A method of preparing a tablet formulation according to any one of the preceding claims, which comprises admixing allopurinol, a disintegrating agent and a granulating agent. A 429 (T)
20. A method of preparing a tablet, which comprises the compression on standard machinery of a formulation according to any one of claims 1 to 18.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2462873A GB1460302A (en) | 1973-05-23 | 1973-05-23 | Tablet formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL44877A0 IL44877A0 (en) | 1974-07-31 |
| IL44877A true IL44877A (en) | 1976-11-30 |
Family
ID=10214700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL44877A IL44877A (en) | 1973-05-23 | 1974-05-22 | Allopurinol tablet formulation |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS577128B2 (en) |
| AT (1) | AT351167B (en) |
| AU (1) | AU469472B2 (en) |
| BE (1) | BE815409A (en) |
| CA (1) | CA977279A (en) |
| CY (1) | CY941A (en) |
| DE (1) | DE2424950A1 (en) |
| DK (1) | DK144261C (en) |
| FI (1) | FI156674A (en) |
| FR (1) | FR2230341B1 (en) |
| GB (1) | GB1460302A (en) |
| HK (1) | HK1378A (en) |
| HU (1) | HU170656B (en) |
| IE (1) | IE39283B1 (en) |
| IL (1) | IL44877A (en) |
| IT (1) | IT8048966A0 (en) |
| KE (1) | KE2808A (en) |
| MY (1) | MY7800181A (en) |
| NL (1) | NL190436C (en) |
| SE (1) | SE402525C (en) |
| ZA (1) | ZA743318B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1533243A (en) * | 1975-02-13 | 1978-11-22 | Wellcome Found | Tablet formulation |
| US4143129A (en) | 1975-10-11 | 1979-03-06 | Lilly Industries Limited | Cephalexin tablets |
| US4115563A (en) * | 1977-03-14 | 1978-09-19 | Sterling Drug Inc. | Pharmaceutical steroid formulation |
| GB1601833A (en) * | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
| DE3839825A1 (en) * | 1988-11-25 | 1990-06-13 | Henning Berlin Gmbh | SOLIDS DISPERSIONS CONTAIN OXIPURINOL AND / OR ITS ALKALI OR EARTH ALKALISALZE |
| EP0719547A1 (en) * | 1994-07-18 | 1996-07-03 | Luis Cipriano Carvajal Martin | Self-desintegrating compact granules used in galenic forms and containing active insoluble or hardly soluble principles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB975850A (en) * | 1955-08-10 | 1964-11-18 | Wellcome Found | Xanthine oxidase inhibitors |
| US3624205A (en) * | 1967-04-25 | 1971-11-30 | Burroughs Wellcome Co | Treatment of hyperuricemia in humans |
-
1973
- 1973-05-23 GB GB2462873A patent/GB1460302A/en not_active Expired
-
1974
- 1974-05-22 JP JP5776774A patent/JPS577128B2/ja not_active Expired
- 1974-05-22 HU HUWE507A patent/HU170656B/hu unknown
- 1974-05-22 FR FR7417820A patent/FR2230341B1/fr not_active Expired
- 1974-05-22 DK DK280174AA patent/DK144261C/en not_active IP Right Cessation
- 1974-05-22 CA CA200,536A patent/CA977279A/en not_active Expired
- 1974-05-22 SE SE7406864A patent/SE402525C/en not_active IP Right Cessation
- 1974-05-22 NL NLAANVRAGE7406873,A patent/NL190436C/en not_active IP Right Cessation
- 1974-05-22 FI FI1566/74A patent/FI156674A/fi unknown
- 1974-05-22 BE BE144636A patent/BE815409A/en not_active IP Right Cessation
- 1974-05-22 IE IE1097/74A patent/IE39283B1/en unknown
- 1974-05-22 AU AU69252/74A patent/AU469472B2/en not_active Expired
- 1974-05-22 ZA ZA00743318A patent/ZA743318B/en unknown
- 1974-05-22 IL IL44877A patent/IL44877A/en unknown
- 1974-05-22 AT AT426774A patent/AT351167B/en not_active IP Right Cessation
- 1974-05-22 DE DE19742424950 patent/DE2424950A1/en active Pending
- 1974-05-23 CY CY941A patent/CY941A/en unknown
- 1974-12-02 KE KE2808A patent/KE2808A/en unknown
-
1978
- 1978-01-05 HK HK13/78A patent/HK1378A/en unknown
- 1978-12-31 MY MY1978181A patent/MY7800181A/en unknown
-
1980
- 1980-06-13 IT IT8048966A patent/IT8048966A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL44877A0 (en) | 1974-07-31 |
| AU469472B2 (en) | 1976-02-12 |
| FR2230341B1 (en) | 1977-04-15 |
| HK1378A (en) | 1978-01-13 |
| MY7800181A (en) | 1978-12-31 |
| AU6925274A (en) | 1975-11-27 |
| DK144261B (en) | 1982-02-01 |
| CA977279A (en) | 1975-11-04 |
| IE39283L (en) | 1974-11-23 |
| NL190436C (en) | 1994-03-01 |
| SE402525B (en) | 1978-07-10 |
| DE2424950A1 (en) | 1974-12-19 |
| JPS577128B2 (en) | 1982-02-09 |
| JPS5040721A (en) | 1975-04-14 |
| IE39283B1 (en) | 1978-09-13 |
| ZA743318B (en) | 1975-05-28 |
| FI156674A (en) | 1974-11-24 |
| NL190436B (en) | 1993-10-01 |
| BE815409A (en) | 1974-11-22 |
| DK144261C (en) | 1991-02-04 |
| AT351167B (en) | 1979-07-10 |
| HU170656B (en) | 1977-07-28 |
| CY941A (en) | 1978-06-23 |
| GB1460302A (en) | 1977-01-06 |
| SE402525C (en) | 1982-11-22 |
| NL7406873A (en) | 1974-11-26 |
| FR2230341A1 (en) | 1974-12-20 |
| IT8048966A0 (en) | 1980-06-13 |
| ATA426774A (en) | 1978-12-15 |
| KE2808A (en) | 1978-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES430431A1 (en) | Direct compression tabletting composition and pharmaceutical tablets produced therefrom | |
| CA2265766A1 (en) | Rapidly disintegrating pellets | |
| GB1421964A (en) | Process for the production of sustained release pharmaceutical preparations | |
| GB1359614A (en) | Method for the manufacture of effervescent tablets | |
| IL44877A (en) | Allopurinol tablet formulation | |
| GB1500441A (en) | Fertilizer | |
| EP0237241A3 (en) | Calcium supplement compressed tablets | |
| GB1464200A (en) | Pharmaceutical composition | |
| GB1356097A (en) | Mineral salt preparation | |
| DE3260227D1 (en) | Composition that contains acesulfame, tablets on the basis of this composition and process for their production | |
| GB1191246A (en) | Vitamin-containing Preparations | |
| GB1221633A (en) | Compositions for hardening teeth and bones | |
| GB1318478A (en) | Cephalexin salts | |
| GB1268146A (en) | Improvements in or relating to a contraceptive cervical obturator | |
| GB1507867A (en) | Edible bran and to a solid edible bran-containing composition and to a process for producing the composition | |
| JPS5342199A (en) | Production of globular titania | |
| GB1347140A (en) | Sodium tripolyphosphate | |
| US3524917A (en) | Tablets of magnesium probenecid tetrahydrate | |
| GB1118606A (en) | Compositions for the treatment of haemorrhoids | |
| AU3809185A (en) | Preparing free-flowing particulate yeast | |
| IL43562A (en) | Pharmaceutical formulations containing allopurinol as inhibitor of xanthine oxidase | |
| GB1287433A (en) | Pharmaceutical compositions | |
| US3655742A (en) | Process for producing magnesium probenecid tetrahydrate | |
| GB1243562A (en) | Process for the production of coloured coatings | |
| IE34705L (en) | Reducing deterioration in hay or straw. |